share_log

Avenue Therapeutics | 10-Q: Q3 2024 Earnings Report

SEC ·  Nov 14 16:24

Summary by Moomoo AI

Avenue Therapeutics, a pharmaceutical company, has been actively engaging in various licensing agreements to bolster its product pipeline and market presence. The company has secured an exclusive license for IV tramadol in the U.S. market from Revogenex and has made upfront and milestone payments totaling $4 million, with additional milestone and royalty payments contingent on FDA approval. Avenue has also extended its supply agreement with Polpharma for IV tramadol, including milestone payments and royalties upon FDA approval. In the realm of neurological disorders, Avenue has acquired exclusive licenses from AstraZeneca and Cincinnati Children's Hospital Medical Center, with upfront fees totaling $3.2 million and potential milestone and royalty payments. Most recently, Avenue entered into an exclusive license agreement with AnnJi Pharmaceutical...Show More
Avenue Therapeutics, a pharmaceutical company, has been actively engaging in various licensing agreements to bolster its product pipeline and market presence. The company has secured an exclusive license for IV tramadol in the U.S. market from Revogenex and has made upfront and milestone payments totaling $4 million, with additional milestone and royalty payments contingent on FDA approval. Avenue has also extended its supply agreement with Polpharma for IV tramadol, including milestone payments and royalties upon FDA approval. In the realm of neurological disorders, Avenue has acquired exclusive licenses from AstraZeneca and Cincinnati Children's Hospital Medical Center, with upfront fees totaling $3.2 million and potential milestone and royalty payments. Most recently, Avenue entered into an exclusive license agreement with AnnJi Pharmaceutical for AJ201, committing to payments totaling over $220 million, including milestone payments and royalties, contingent on the product's clinical and commercial success. Avenue has also issued common stock to AnnJi as part of the agreement. The company has not reported any leases, litigation, or significant changes in accounts payable and accrued expenses. Avenue's stockholder's equity has been affected by a reverse stock split and the authorization of additional common stock. The company has also engaged in capital raising activities, including warrant inducements and private placements, and has established an ATM facility with H.C. Wainwright & Co. for the sale of common stock.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated